ACC 2013

ASTRONAUT Study: No Significant Post-Discharge Mortality Benefit Seen with Aliskiren

By March 11, 2013

The results of the ASTRONAUT study revealed that aliskiren did not improve post-discharge mortality and/or hospitalizations when added to standard therapy in recently hospitalized patients with worsening chronic heart failure and reduced ejection fraction, stated Mihai Gheorghiade, MD, from the Center for Cardiovascular Innovation, Northwestern University Feinberg School of Medicine, Chicago, IL.

Prasugrel Reload Dosing Regimen Reduces High On-Treatment Platelet Reactivity Rates

By March 11, 2013

Patients with acute coronary syndrome on maintenance dose prasugrel had a reduction in high on-treatment platelet reactivity rates after a prasugrel reload strategy, according to a post hoc analysis of a prospective, randomized, open-label pharmacodynamic study presented at ACC.13, the American College of Cardiology's 62nd Annual Scientific Session.

Positive Thrombotic and Thrombolytic Effects Observed with PAR-1 Antagonist Vorapaxar

By March 11, 2013

Vorapaxar, a novel, oral PAR-1 agonist that inhibits thrombin-induced platelet activation, was found to prolong occlusion time and shorten lysis time, with a favorable effect on thrombotic and thrombolytic status, results of a study presented at ACC.13, the American College of Cardiology's 62nd Annual Scientific Session, has found.

RELAX Study: No Significant Benefit of PDE-5 Inhibitors Observed in Heart Failure

By March 11, 2013

Administration of an erectile dysfunction medication provided no beneficial effects in diastolic heart failure patients as stated by Margaret Redfield, MD from the Mayo Clinic in Rochester, MN.

Aspirin + Clopidogrel Post-CABG Improve Overall Bypass Graft Patency

By March 11, 2013

The immediate post-operative addition of clopidogrel to aspirin after coronary artery bypass grafting (CABG) proved to be safe and improved overall graft patency, according to data presented at ACC.13, the American College of Cardiology's 62nd Annual Scientific Session.

Novel Omega-3 Free Fatty Acid Formulation Reduces Non-HDL-C in High-Risk Patients on Statins

By March 11, 2013

A novel formulation of omega-3 free fatty acids (OM3-FFA) at a dosage as low as 2g/d was effective and well tolerated in lowering non-high density lipoprotein cholesterol (non-HDL-C), triglycerides (TG), and other markers of cardiovascular risk—including Apo CIII and Lp-PLA2—in patients with persistent hypertriglyceridemia on statin therapy, according to a study presented at ACC.13, the American College of Cardiology's 62nd Annual Scientific Session.

In Patients with Heart Failure, Allopurinol Reduces Incidence of Atrial Fibrillation

By March 11, 2013

Allopurinol reduced the incidence of atrial fibrillation (AF) in patients with heart failure, a retrospective cohort study presented at ACC.13, the American College of Cardiology's 62nd Annual Scientific Session, has found.

Low-Dose Diuretic Favorable in Patients with Chronic Heart Failure

By March 11, 2013

Reduction of furosemide dose in stable patients with chronic heart failure (HF) is feasible, with no deterioration in clinical status, a study presented at ACC.13, the American College of Cardiology's 62nd Annual Scientific Session, has found.

Pitavastatin More Beneficial than EPA in Decreasing Plaque Vulnerability

By March 11, 2013

Pitavastatin has beneficial effects on a marker of oxidative stress and pericellular MT1-MMP activity in hypercholesterolemic patients compared with eicosapentaenoic acid (EPA), according to a study at ACC.13, the American College of Cardiology's 62nd Annual Scientific Session.

Pitavastatin Effective Alternative in Otherwise Statin-Intolerant Patients

By March 11, 2013

Pitavastatin is an acceptable alternative for patients who are intolerant to other statins, according to research presented at ACC.13, the American College of Cardiology's 62nd Annual Scientific Session by Bobby Hollaway, CNA, from the Intermountain Medical Center, Murray, UT.

Early Intensive Atorvastatin Protects Endothelial Function and Reduces Inflammation

By March 11, 2013

At ACC.13, the American College of Cardiology's 62nd Annual Scientific Session, Riccardo Raddino, MD, from the University of Bresci and Civil Hospital, Bresci, Italy, presented data demonstrating that early intensive atorvastatin therapy results in great protection of endothelial function and reduction of vascular inflammation than a moderate dose.

Prasugrel Reduces Post-PCI Risk in Patients with High On-Clopidogrel Platelet Reactivity

By March 11, 2013

Prasugrel, compared with high-dose clopidogrel, more effectively reduced the risk of vascular mortality or stent thrombosis following a percutaneous coronary intervention (PCI) in patients with high on-clopidogrel platelet reactivity (HPR), according to data presented at ACC.13, the American College of Cardiology's 62nd Annual Scientific Session.

Ezetimibe Proves Effective in Children with High-Risk Dyslipidemia

By March 11, 2013

Ezetimibe 10mg/day administered in 6-10 years old children with heterozygous familial or non-familial primary hypercholesterolemia provided significant reductions in LDL-C as well as other lipid parameters after 12 weeks of therapy, as presented at ACC.13, the American College of Cardiology's 62nd Annual Scientific Session.

Omega-3 Fatty Acid Reduces Risk of Developing Atrial Fibrillation

By March 11, 2013

At ACC.13, the American College of Cardiology's 62nd Annual Scientific Session, researchers presented that in post-cardiac surgery patients, omega-3 fatty acids (PUFA) therapy significantly reduces the risk of developing atrial fibrillation.

Statins Administered Before Primary Intervention Associated with Cardioprotective Effects

By March 11, 2013

Statin therapy administered before primary intervention in acute myocardial infarction (AMI) patients was not associated with reduced risk of all-cause death and major adverse cardiac and cerebrovascular events (MACE) as presented by Mitsuhiro Shimomura, MD, and colleagues from the Department of Cardiovascular Medicine, Saga University in Saga, Japan.

Ranolazine Reduces Frequency of Angina in Patients with Diabetes, CAD

By March 10, 2013

Ranolazine was more effective than placebo in reducing angina frequency and sublingual nitroglycerin (SL NTG) use in patients with type 2 diabetes, coronary artery disease, and chronic angina, according to results of a study presented at ACC.13, the American College of Cardiology's 62nd Annual Scientific Session.

Eplerenone + Standard of Care Improves Outcomes in Patients with STEMI

By March 10, 2013

Adding eplerenone to standard therapy within 24 hours of symptom onset improved outcomes in patients presenting with acute ST-elevation myocardial infarction (STEMI) who had no evidence of heart failure (HF) or left ventricular ejection fraction (LVEF) <40%, results of the REMINDER trial presented at ACC.13, the American College of Cardiology's 62nd Annual Scientific Session, has found.

Bivalirudin Superior to Heparin in 'Real World' Patients with ACS Undergoing PCI + Coronary Stenting

By March 10, 2013

Use of bivalirudin alone was superior to heparin alone with respect to all-cause mortality in patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI) plus coronary stenting, results of a study presented at ACC.13, the American College of Cardiology's 62nd Annual Scientific Session has found.

IV Magnesium Enhances Ibutilide in Atrial Fibrillation/Flutter Conversion

By March 10, 2013

Srikanth Vallurupalli, MD, and colleagues from the University of Arkansas Medical Sciences, Little Rock, AR presented results at ACC.13, the American College of Cardiology's 62nd Annual Scientific Session, in support of intravenous (IV) magnesium significantly enhancing the efficacy of ibutilide in atrial fibrillation conversion and flutter.

Pediatric Patients with Dilated Cardiomyopathy May Benefit from Carvedilol Treatment

By March 10, 2013

Children with dilated cardiomyopathy have increased risk of transplantation and mortality, particularly within the first year of presentation, and may benefit from treatment with carvedilol and ACE inhibitors, a 14-year review of treating this patient population concluded at ACC.13, the American College of Cardiology's 62nd Annual Scientific Session.

Second-Generation Drug-Eluting Stents Reduces Target Lesion Failure in AMI Patients

By March 10, 2013

Treatment with second-generation drug-eluting stents (DES) is associated with decreased target lesion failure compared with bare metal stents (BMS) in patients with acute myocardial infarction (AMI), a study reported at ACC.13, the American College of Cardiology's 62nd Annual Scientific Session.

Net Clinical Benefit of Rivaroxaban for Thrombosis Prevention in ACS Patients

By March 10, 2013

After reports of having met the primary endpoints in the ATLAS-ACS TIMI-52 study, rivaroxaban 2.5mg and 5mg demonstrated a benefit over placebo in terms of cardiac mortality and bleeding risk as presented at ACC.13, the American College of Cardiology's 62nd Annual Scientific Session.

Mineralocorticoid Receptor Antagonist Use in Patients with Diabetes Needs Closer Scrutiny

By March 10, 2013

Patients with diabetes mellitus and reduced ejection fraction that received mineralocorticoid receptor antagonists (MRAs) "demonstrated a different clinical profile" compared with patients who did not receive an MRA, according to a presentation at ACC.13, the American College of Cardiology's 62nd Annual Scientific Session.

Linear Correlation Supports Common Mechanism of Action for Ranolazine

By March 10, 2013

At ACC.13, the American College of Cardiology's 62nd Annual Scientific Session, Ramin Farzaneh-Far, MD, FACC, from Gilead Sciences, Foster City, CA, reported that the QTc interval shortening and anti-ischemic effect of ranolazine provide evidence of a similar mechanism of action, such as inhibition of late sodium current (INA,L).

Heart Failure Progression Delayed with Metformin Treatment

By March 10, 2013

Metformin may delay progression during early stages of heart failure, a retrospective observational study conducted in patients with left ventricular hypertrophy (LVH) presented at ACC.13, the American College of Cardiology's 62nd Annual Scientific Session, has found.

No Association between CCBs, Diabetes Mellitus Found in Asian Patients with CVD

By March 10, 2013

A study of more than 4,000 patients found no clear association between calcium channel blocker (CCB) therapy and new-onset diabetes in an Asian population with cardiovascular disease, a study to explore this controversy concluded at ACC.13, the American College of Cardiology's 62nd Annual Scientific Session.

UFH + Clopidogrel Reduces In-Hospital Mortality in STEMI Patients Not Undergoing Reperfusion

By March 10, 2013

The combination of unfractionated heparin (UFH) and clopidogrel was associated with a reduced risk of in-hospital morality, with benefits consistent across all age groups, a study presented at ACC.13, the American College of Cardiology's 62nd Annual Scientific Session has found.

Patients with Primary Vascular Dysregulation Benefit from Triflusal vs. ASA

By March 10, 2013

Triflusal more effectively and consistently improved symptoms and blood flow in patients with primary vascular dysregulation (PVD) compared with acetylsalicylic acid (ASA) and should be considered a treatment option in this population, results of study presented at ACC.13, the American College of Cardiology's 62nd Annual Scientific Session have found.

Dual RAAS Blockade with Valsartan Induces Long-Term Benefit in Patients with HF

By March 10, 2013

Patients with systolic congestive heart failure, including those with early worsening of renal function and renal dysfunction at baseline, had long-term benefits from dual renin-angiotensin-aldosterone system (RAAS) blockade in the addition of valsartan to angiotensin-converting enzyme (ACE) inhibitor, in a post hoc analysis of results from the Valsartan in Heart Failure Trial (Val-HeFT) as concluded in a presentation at ACC.13, the American College of Cardiology's 62nd Annual Scientific Session.

Carvedilol Superior to Metoprolol in Mortality Reductions for Heart Failure

By March 10, 2013

At ACC.13, the American College of Cardiology's 62nd Annual Scientific Session, study authors presented that carvedilol compared to metoprolol was associated with a significant reduction in heart failure hospitalizations, death, and ventricular arrhythmias.